Update shared on 14 Dec 2025
Fair value Increased 0.37%Analysts have inched up their price target on WuXi Biologics (Cayman) to approximately $39.54 from about $39.39, citing slightly lower perceived risk, expectations for steady high teens revenue growth, and a modestly improved long term profit margin outlook that more than offsets a marginally lower assumed future P E multiple.
What's in the News
- Signed a strategic Memorandum of Understanding with Qatar Free Zones Authority to establish WuXi Biologics' first integrated CRDMO center in the Middle East. This will expand its global network and support the development of a regional biopharmaceutical ecosystem (Key Developments).
- Announced TrueSite TI, a fourth generation targeted integration based CHO cell line platform designed to shorten IND timelines, improve product quality, and enhance scalability for antibody and complex protein therapies (Key Developments).
- Reported that the TrueSite TI platform, built on the proven WuXia cell line family, delivers high titer, long term expression stability and consistent pool to clone quality across more than 1,000 validated molecules, supporting faster and more reliable biologics development (Key Developments).
Valuation Changes
- Fair Value Estimate has risen slightly to approximately HK$39.54 from about HK$39.39 per share, reflecting a marginally more optimistic outlook.
- Discount Rate has fallen slightly to roughly 7.98% from about 8.03%, indicating a modest reduction in perceived risk.
- Revenue Growth Assumption is essentially unchanged, remaining around 16.1% in the high teens range.
- Net Profit Margin has risen slightly to about 21.55% from roughly 21.47%, pointing to a modest improvement in long term profitability expectations.
- Future P/E Multiple has edged down slightly to about 26.4x from approximately 26.5x, partially offsetting the positive impact of higher margin assumptions.
Have other thoughts on WuXi Biologics (Cayman)?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.